Comments
Votrient shows some cancer survival gains: FDA
17.03.2012. | WASHINGTON (Reuters) - GlaxoSmithKline Plc's Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did not improve overall survival rates, U.S. health regulators said on Friday....
